Active ingredientFilgotinibCat. No. P-F044-001CAS 1206161-97-8Family · Pharmaceutical analytical standards
Filgotinib
A Janus kinase inhibitor with a preference for JAK1, taken by mouth: approved in September 2020 in the European Union and Japan for moderate to severe active rheumatoid arthritis in adults. This family brings together the active ingredient and labelled standards.
Did you know?It was developed by a Belgian-Dutch biotech company and, curiously, it is not broken down by the liver's cytochrome P450 enzymes but by carboxylesterases.
Go to the active ingredient →Active ingredientFilgotinibCat. No. P-F044-001CAS 1206161-97-8
Isotopically labelledFilgotinib-d4Cat. No. P-F044-002CAS 2041095-50-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.